Early safety check for new diabetes drug combo
NCT ID NCT07158346
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This early-phase study tested how two experimental drugs (L03RD1 and L03RD2) move through the body and their safety when given together or as a single combined drug (CT-L03). It involved 49 healthy adults aged 19-55. The goal was to gather basic information, not to treat diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H plus Yangji Hostpital
Seoul, 08756, South Korea
Conditions
Explore the condition pages connected to this study.